ViiV Healthcare secures Canadian approval for HIV drug regimen CABENUVA

This article was originally published here

CABENUVA is now the first once-monthly, complete long-acting regimen for the treatment of HIV-1 in adults, which has been indicated to replace the current antiretroviral (ARV) regimen in

The post ViiV Healthcare secures Canadian approval for HIV drug regimen CABENUVA appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply